HLS Therapeutics (TSX:HLS) Tariff Resilience Score: 6/10 (As of Jul. 01, 2026)


TSX:HLS HLS Therapeutics Inc TSX:HLS
62 GF Score
Price C$4.41
GF Value C$4.47
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Tariff Resilience Score?

HLS Therapeutics TSX:HLS +3.52% 62 Tariff Resilience Score is 6 as of Jul. 01, 2026. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,029 Drug Manufacturers companies, HLS Therapeutics ranks better than 91.16% on this metric.

HLS Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

HLS Therapeutics has Moderate exposure due to pharmaceutical imports and exports. Relies on global supply chains but has some pricing power and alternative supplier options to mitigate tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes HLS Therapeutics might have Average Resilient.

HLS Therapeutics  (TSX:HLS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

HLS Therapeutics Tariff Resilience Score Related Terms

TSX:HLS vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Tariff Resilience Score falls into.


TSX:HLS
62GF Score
HLS Therapeutics Inc TSX:HLS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
HLS Therapeutics (TSX:HLS) has a Tariff Resilience Score of 6 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, HLS Therapeutics ranks #91 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is HLS Therapeutics' Tariff Resilience Score too high?
HLS Therapeutics' current Tariff Resilience Score is 6. Based on the distribution chart, HLS Therapeutics ranks #91 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #91 out of 1029 companies for Tariff Resilience Score. This places HLS Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. HLS Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.41 — trading 1.3% below its estimated fair value. The current Tariff Resilience Score is 6. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Tariff Resilience Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.41 is trading 1.3% below its estimated GF Value™ of C$4.47. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Tariff Resilience Score: 6
  • GF Value™: C$4.47 vs. price of C$4.41 (1.3% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score

Get the complete analysis for TSX:HLS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.41
Price
C$4.47
GF Value